Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
CAR T-cell therapy in multiple myeloma: mission accomplished?
B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells are the most
potent treatment against multiple myeloma (MM). Here, we review the increasing body of …
potent treatment against multiple myeloma (MM). Here, we review the increasing body of …
Current understanding and management of CAR T cell-associated toxicities
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of several
haematological malignancies and is being investigated in patients with various solid …
haematological malignancies and is being investigated in patients with various solid …
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024: Featured Updates to the NCCN Guidelines
JA Thompson, BJ Schneider, J Brahmer… - Journal of the National …, 2024 - jnccn.org
The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are
intended to provide oncology practitioners with guidance on how to manage the wide …
intended to provide oncology practitioners with guidance on how to manage the wide …
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
We report a first-in-human clinical trial using chimeric antigen receptor (CAR) T cells
targeting CD37, an antigen highly expressed in B-and T-cell malignancies. Five patients …
targeting CD37, an antigen highly expressed in B-and T-cell malignancies. Five patients …
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Ciltacabtagene autoleucel (cilta-cel) was approved in 2022 for patients with
relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the …
relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the …
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain
Multiple myeloma (MM) is a rarely curable malignancy of plasma cells. MM expresses B cell
maturation antigen (BCMA). We developed a fully human anti-BCMA chimeric antigen …
maturation antigen (BCMA). We developed a fully human anti-BCMA chimeric antigen …
Mechanisms and management of CAR T toxicity
Chimeric antigen receptor (CAR) T cell therapies have dramatically improved treatment
outcomes for patients with relapsed or refractory B-cell acute lymphoblastic leukemia, large …
outcomes for patients with relapsed or refractory B-cell acute lymphoblastic leukemia, large …
The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma
Introduction Despite remarkable therapeutic advances over the last two decades, which
have resulted in dramatic improvements in patient survival, multiple myeloma (MM) is still …
have resulted in dramatic improvements in patient survival, multiple myeloma (MM) is still …
New horizons in our understanding of precursor multiple myeloma and early interception
Multiple myeloma is an incurable plasma cell malignancy that evolves over decades through
the selection and malignant transformation of monoclonal plasma cells. The evolution from …
the selection and malignant transformation of monoclonal plasma cells. The evolution from …
BCMA-CAR T-cell treatment–associated parkinsonism
In this issue of Blood, Graham et al 1 and Karschnia et al 2 provide new insights into the rare
hypokinetic movement disorder (also termed movement and neurocognitive treatment …
hypokinetic movement disorder (also termed movement and neurocognitive treatment …